^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD123 (Interleukin 3 Receptor Subunit Alpha)

    i
    Other names: IL3RA, Interleukin 3 receptor subunit alpha, CD123, Interleukin 3 Receptor Alpha, IL-3 Receptor Subunit Alpha, IL-3R Subunit Alpha, CD123 Antigen, IL-3R-Alpha, IL-3RA , IL3R, IL-3 Receptor Alpha SP2 Isoform
    5d
    Recent advances in CAR T and CAR NK cell therapy for AML. (PubMed, Int J Hematol)
    In this review, we will describe the current status of CAR T/NK cell development for AML. We will also introduce a new CAR T-cell or NK-cell therapy that targets mismatched HLA-DRB1 in patients with AML who have relapsed following an allogeneic haematopoietic stem cell transplant.
    Review • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    5d
    Treatment of acute myeloid leukemia using CD3/CD123 bispecific antibody-engaged γδT cells in a mouse xenograft model. (PubMed, Tissue Cell)
    The CD3/CD123 BsAbs effectively redirects γδ T cells to selectively target and eliminate AML cells, providing a promising immunotherapeutic strategy for the treatment of AML.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    7d
    Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma. (PubMed, Haematologica)
    Both BCMA and CD307e were more highly expressed on BM plasma-cells than CTPCs. This study is among the first to provide a comprehensive phenotypic characterisation of CD56+ CTPCs across the MM spectrum, including checkpoint and chemokine receptors, treated disease cases, and paired BM samples for NDMM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR6 (C-C Motif Chemokine Receptor 6) • HLA-C (Major Histocompatibility Complex, Class I, C) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    15d
    Protective Effect of Idebenone Against UVB-Induced Photoaging in HaCaT Cells. (PubMed, Drug Des Devel Ther)
    IDE significantly improved UVB-induced photoaging damage in HaCaT cells through multiple pathways, including restoring cell viability, alleviating oxidative stress damage, reducing pro-inflammatory factor infiltration, and protecting mitochondrial function. Its mechanism of action may involve the regulation of targets such as IL-3RA and TUBA8.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL1B (Interleukin 1, beta)
    19d
    Aptamer-targeted hybrid nanoparticles based on human exosomes and LXR agonist-loaded liposomes for enhanced anti-AML therapy. (PubMed, Nucleosides Nucleotides Nucleic Acids)
    In vivo, A-ELHN@T0901317 group exhibited a substantially smaller fold increase in tumor fluorescence (21.38 ± 5.428-fold) than the control group (61.57 ± 17.73-fold, p < 0.0001), while significantly reduced damage to normal organs. Our findings suggest that A-ELHN@T0901317 represents a novel delivery method for the treatment of AML and highlights a promising direction for tumor-targeted therapy.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • FASN (Fatty acid synthase) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • ABCG1 (ATP Binding Cassette Subfamily G Member 1) • SCD (Stearoyl-CoA Desaturase)
    20d
    Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry. (PubMed, Cytometry B Clin Cytom)
    CD123 is frequently expressed on neoplastic MCs in SM by flow cytometry, across all subtypes. These findings support further investigation of CD123 as a therapeutic target and warrant correlation with IHC and clinical outcomes in larger cohorts.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    TNFRSF8 expression • IL2RA expression
    20d
    Molecular immune signature identifies microglia and NK cell infiltration as a favorable prognostic marker in adult-type high-grade glioma. (PubMed, ESMO Open)
    These integrated findings underscore the beneficial immune microenvironment in LTS HGG driven by specific innate and adaptive immune components. This immune signature may serve as a prognostic indicator and guide immunomodulatory therapeutic strategies for gliomas.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NOS2 (Nitric Oxide Synthase 2)
    1m
    Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation. (PubMed, Ann Med)
    Multidimensional technological innovation and the synergistic optimization of combination therapies are critical to overcoming AML-specific barriers. These advances hold the potential to unlock the precise clinical application of CAR-T therapy, ultimately improving survival outcomes for patients with relapsed/refractory AML.
    Preclinical • Review • Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    1m
    Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study. (PubMed, J Pathol Clin Res)
    In conclusion, this multicenter study suggests that most MS are of myelomonocytic/monoblastic origin, a high proportion of them are NPM1 mutated, and may lack expression of MPO and CD34. NPM1 mutation-specific antibodies should be integrated into the diagnostic panels for MS or LC, while IRF8 and PU.1 are not recommended as they cannot distinguish MS from histiocytic neoplasms.
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • IRF8 (Interferon Regulatory Factor 8) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • MPO (Myeloperoxidase)
    |
    BRAF V600E • NPM1 mutation
    1m
    IL3RA identified as novel biomarker and therapeutic target for ER+ breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis. (PubMed, Clin Proteomics)
    Our study identified IL3RA as novel biomarker and therapeutic target for ER+ breast cancer. Further validation and mechanistic studies are warranted to advance precision oncology strategies for ER+ breast cancer management.
    Journal
    |
    ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    ER positive
    |
    Farydak (panobinostat)
    1m
    CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV
    2ms
    Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    MB-101